Δημοσιεύσεις

  • ΠΡΩΤΟΤΥΠΑ ΕΡΕΥΝΗΤΙΚΑ ΑΡΘΡΑ

    1.       Kwa A, Kasiakou SK,Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin(polymyxin E). Expert Rev Anti Infect Ther. 2007 Oct;5(5):811-21.
    2.       Falagas ME, Kasiakou SK.Local administration of polymyxins into the respiratory tract for theprevention and treatment of pulmonary infections in patients without cysticfibrosis. Infection. 2007 Feb;35(1):3-10.
    3.       Falagas ME, Rafailidis PI, KasiakouSK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity ofcolistin monotherapy vs. colistin-meropenem combination therapy formultidrug-resistant Gram-negative bacterial infections. Clin MicrobiolInfect. 2006 Dec;12(12):1227-30.
    4.       Falagas ME, Kasiakou SK,Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity ofintravenous colistin for treatment of patients with infections due topolymyxin-only-susceptible (POS) gram-negative bacteria. Eur J ClinMicrobiol Infect Dis. 2006 Sep;25(9):596-9.
    5.       Falagas ME, Kasiakou SK,Michalopoulos A. Polymyxins: a word of caution for prudent use of valuable"old antibiotics". Infect Control Hosp Epidemiol. 2006Sep;27(9):995.
    6.       Falagas ME, Kasiakou SK,Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxinsfor the treatment of infections in critically ill patients: a review of therecent literature. Clin Med Res. 2006 Jun;4(2):138-46.
    7.       Falagas ME, Kasiakou SK,Nikita D, Morfou P, Georgoulias G, Rafailidis PI. Secular trends ofantimicrobial resistance of blood isolates in a newly founded Greek hospital. BMCInfect Dis. 2006 Jun 15;6:99.
    8.       Bliziotis IA, KapaskelisAM, Kasiakou SK, Falagas ME. Limitations in the management of aorticgraft infections. Ann Vasc Surg. 2006 Sep;20(5):669-71.
    9.       Falagas ME, Kasiakou SK.Use of international units when dosing colistin will help decrease confusionrelated to various formulations of the drug around the world. AntimicrobAgents Chemother. 2006 Jun;50(6):2274-5.
    10.    Falagas ME, Kasiakou SK,Rafailidis PI, Zouglakis G, Morfou P. Comparison of mortality of patients with Acinetobacterbaumannii bacteraemia receiving appropriate and inappropriate empiricaltherapy. J Antimicrob Chemother. 2006 Jun;57(6):1251-4.
    11.    Falagas ME, Kasiakou SK.Toxicity of polymyxins: a systematic review of the evidence from old and recentstudies. Crit Care. 2006 Feb;10(1):R27.
    12.    Bliziotis IA, KasiakouSK, Kapaskelis AM, Falagas ME. Mesh-related infection after hernia repair:case report of an emerging type of foreign-body related infection. Infection.2006 Feb;34(1):46-8.
    13.    Falagas ME, Kasiakou SK.Correct use of the term 'pan-drug-resistant' (PDR) Gram-negative bacteria. ClinMicrobiol Infect. 2005 Dec;11(12):1049-50.
    14.    Kasiakou SK, Lawrence KR, Choulis N,Falagas ME. Continuous versus intermittent intravenous administration ofantibacterials with time-dependent action: a systematic review ofpharmacokinetic and pharmacodynamic parameters. Drugs.2005;65(17):2499-511.
    15.    Falagas ME, Fragoulis KN, KasiakouSK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin:a prospective evaluation. Int J Antimicrob Agents. 2005 Dec;26(6):504-7.
    16.    Kasiakou SK, Fragoulis K, TzagarakisG, Mistidis P, Kapaskelis A, Falagas ME. Cure of multidrug-resistant Acinetobacterbaumannii fixation device-related orthopedic infections in two patientswith intravenous colistin. Microb Drug Resist. 2005 Fall;11(3):287-9.
    17.    Bliziotis IA, MichalopoulosA, Kasiakou SK, Samonis G, Christodoulou C, Chrysanthopoulou S, FalagasME. Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam forthe treatment of febrile neutropenia: a meta-analysis of randomized controlledtrials. Mayo Clin Proc. 2005 Sep;80(9):1146-56.
    18.    Michalopoulos A, KasiakouSK, Falagas ME. The significance of different formulations of aerosolizedcolistin. Crit Care. 2005 Aug;9(4):417-8; author reply 417-8.
    19.    Kasiakou SK, Sermaides GJ,Michalopoulos A, Soteriades ES, Falagas ME. Continuous versus intermittentintravenous administration of antibiotics: a meta-analysis of randomisedcontrolled trials. Lancet Infect Dis. 2005 Sep;5(9):581-9.
    20.    Kasiakou SK, Michalopoulos A,Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy withintravenous colistin for management of infections due to multidrug-resistantGram-negative bacteria in patients without cystic fibrosis. AntimicrobAgents Chemother. 2005 Aug;49(8):3136-46.
    21.    Bliziotis IA, KasiakouSK, Baloyanni M, Falagas ME. A healthy woman with right upper quadrantdiscomfort on deep palpation. Am Fam Physician. 2005 Jun15;71(12):2353-5.
    22.    Kasiakou SK, Peppas G, Kapaskelis AM,Falagas ME. Regression of skin lesions of Kyrle's disease with clindamycin:implications for an infectious component in the etiology of the disease. JInfect. 2005 Jun;50(5):412-6.
    23.    Falagas ME, Kasiakou SK,Michalopoulos A. Treatment of multidrug-resistant Pseudomonas aeruginosa andAcinetobacter baumannii pneumonia. J Cyst Fibros. 2005 May;4(2):149-50.
    24.    Rosmarakis ES, SoteriadesES, Vergidis PI, Kasiakou SK, Falagas ME. From conference abstract tofull paper: differences between data presented in conferences and journals. FASEBJ. 2005 May;19(7):673-80.
    25.    Kasiakou SK, Rafailidis PI,Liaropoulos K, Falagas ME. Cure of post-traumatic recurrent multiresistantGram-negative rod meningitis with intraventricular colistin. J Infect.2005 May;50(4):348-52.
    26.    Rafailidis PI, Prapas SN, KasiakouSK, Costeas XF, Falagas ME. Effusive-constrictive calcific pericarditisassociated with Streptococcus salivarius. Case report and review of theliterature. Cardiol Rev. 2005 May-Jun;13(3):113-7.
    27.    Falagas ME, Kasiakou SK.Colistin: the revival of polymyxins for the management of multidrug-resistantgram-negative bacterial infections. Clin Infect Dis. 2005 May1;40(9):1333-41.
    28.    Falagas ME, Bliziotis IA, KasiakouSK, Samonis G, Athanassopoulou P, Michalopoulos A.  Outcome of infections due topandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis. 2005 Apr8;5(1):24.
    29.    Rosmarakis ES, KapaskelisAM, Kasiakou SK, Falagas ME. Case report: Wegener's granulomatosispresents as pulmonary infection. Am Fam Physician. 2005 Mar15;71(6):1062, 1064.
    30.    Michalopoulos A, KasiakouSK, Rosmarakis ES, Falagas ME. Cure of multidrug-resistant Acinetobacterbaumannii bacteraemia with continuous intravenous infusion of colistin. ScandJ Infect Dis. 2005;37(2):142-5.
    31.    Michalopoulos A, KasiakouSK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME.  Aerosolized colistin for the treatment ofnosocomial pneumonia due to multidrug-resistant Gram-negative bacteria inpatients without cystic fibrosis. Crit Care. 2005 Feb;9(1):R53-9.
    32.    Falagas ME, Kasiakou SK.Mesh-related infections after hernia repair surgery. Clin Microbiol Infect.2005 Jan;11(1):3-8.
    33.    Falagas ME, Rizos M,Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity afterprolonged (more than four weeks) administration of intravenous colistin. BMCInfect Dis. 2005 Jan 10;5(1):1.
    34.    Falagas ME, Kasiakou SK,Michalopoulos A. Antimicrobial resistance of Acinetobacter spp. in Europe. ClinMicrobiol Infect. 2004 Dec;10(12):1106-7.
    35.   KasiakouSK,Rafailidis PI, Rosmarakis ES, Falagas ME. Recurrent omphalitis in adults. Scand J Gastroenterol. 2004 Oct;39(10):1021-4.
     
  • ΠΕΡΙΛΗΨΕΙΣ ΑΡΘΡΩΝ ΣΕ ΔΙΕΘΝΗ ΣΥΝΕΔΡΙΑ

    1.       Pefanis A, Kasiakou S,Papaetis, et al. Endocarditis and spondylitis due to community-acquiredmethicillin-resistant Staphylococcus aureus (CA-MRSA)—a case report. Clin ResCardiol. 96:406. In: Abstracts of the Ninth International Symposium of ModernConcepts in Endocarditis and Cardiovascular Infections, 2007
    2.       Kasiakou SK, Lawrence K, Choulis N,Falagas ME. Continuous versus intermittent intravenous administration ofantibiotics with time-dependent anti-bacterial action: a systematic review ofpharmacokinetic and pharmacodynamic parameters. 16th European Congress ofClinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April2006
    3.       Falagas ME, Fragoulis K, KasiakouS, Sermaides G, Michalopoulos A. Nephrotoxicity of intravenous colistin: aprospective evaluation. 16th European Congress of Clinical Microbiology andInfectious Diseases (ECCMID), Nice, France, April 2006
    4.       Rafailidis P, Kasiakou S,Morfou P, Georgoulias G, Nikita D, Falagas ME. Secular trends of antimicrobialresistance of blood isolates in a newly founded Greek hospital. 16th EuropeanCongress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice,France, April 2006
    5.       Kofteridis DP, Falagas M, KasiakouS, Roditakis G, Alegakis D, Samonis G. Hospital-acquiredmultidrug-resistant Gram-negative infections: clinical features, treatment, andoutcome.  Presented at the 45thInterscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC),Washington, DC, December, 2005
    6.       Kasiakou SK, Michalopoulos A,Soteriades E, Samonis G, Sermaides G, Falagas ME. Intravenous colistin fortreatment of infections due to multidrug-resistant Gram-negative bacteria inpatients without cystic fibrosis. 15th European Congress of ClinicalMicrobiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April, 2005
    7.       Kasiakou SK, Michalopoulos A,Rosmarakis E, Vergidis PI, Falagas ME. Cure of multidrug-resistant (MDR)Acinetobacter baumannii bacteraemia with continuous intravenous infusion ofcolistin. 15th European Congress of Clinical Microbiology and InfectiousDiseases (ECCMID), Copenhagen, Denmark, April, 2005
    8.       Falagas ME, Rizos M,Bliziotis I, Kasiakou SK, Michalopoulos A. Toxicity after prolonged(more than four weeks) administration of intravenous colistin. 15th EuropeanCongress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen,Denmark, April, 2005
    9.       Kasiakou SK, Rosmarakis E, Peppas G,Kapaskelis A, Sergounioti A, Falagas ME. Regression of skin lesions of Kyrle’sdisease with clyndamycin: implications for an infectious component in theaetiology of the disease. 15th European Congress of Clinical Microbiology andInfectious Diseases (ECCMID), Copenhagen, Denmark, April, 2005
    10.    Kasiakou SK, Sermaides G, MichalopoulosA, Soteriades E, Falagas ME. Continuous versus intermittent administration ofantibiotics: a meta-analysis of randomised controlled trials. 15th EuropeanCongress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen,Denmark, April, 2005
    11.    Kasiakou SK, Fragoulis K, TzagarakisG, Mistidis P, Kapaskelis A, Falagas ME. Cure of multidrug-resistantAcinetobacter baumannii prosthetic material-related orthopaedic infections withintravenous colistin.  15th European Congressof Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark,April, 2005
    12.    Kasiakou SK, Rafailidis P, LiaropoulosK, Bliziotis I, Chelvatzoglou F, Falagas ME. Cure of post-traumatic recurrentmultiresistant Gram-negative rod meningitis with intravenrticular colistin.15th European Congress of Clinical Microbiology and Infectious Diseases(ECCMID), Copenhagen, Denmark, April, 2005
    13.    Michalopoulos A, KasiakouSK, Mastora Z, Rellos K, Kapaskelis A, Falagas ME. Aerosolized colistin forthe treatment of nosocomial pneumonia due to multidrug-resistant Gram-negativebacteria in patients without cystic fibrosis. 15th European Congress ofClinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark,April, 2005
    14.    Bliziotis I, MichalopoulosA, Kasiakou SK, Samonis G, Christodoulou C, Chrysanthopoulou S, FalagasME. Ciprofloxacin versus an aminoglycoside as combination therapy to a betalactam for the treatment of febrile neutropenia: a meta-analysis of randomisedcontrolled trials. 15th European Congress of Clinical Microbiology andInfectious Diseases (ECCMID), Copenhagen, Denmark, April, 2005
    15.    Kasiakou SK, Kapaskelis AM,Paraschakis K, Chelvatzoglou FC, Sergounioti AE, Falagas ME. Continuous versusintermittent intravenous administration of antibiotics: a systematic review ofclinical trials. Presented at the 42nd Annual Meeting of IDSA, Boston, MA,September 2004
    16.    Falagas ME, Tsiodras S,Rellos K, Mentzelopoulos S, Kasiakou SK, Michalopoulos A.Effectiveness and safety of colistin treatment in patients with ICU-acquiredinfections due to multiresistant gram-negative bacteria: the renaissance of anold antibiotic. Presented at the 42nd Annual Meeting of IDSA, Boston, MA,September 2004
     
  • ΠΕΡΙΛΗΨΕΙΣ ΑΡΘΡΩΝ ΣΕ ΕΛΛΗΝΙΚΑ ΣΥΝΕΔΡΙΑ

    1.       Γ. Ξυλωμένος, Σ. Κασιάκου,Κ. Ντίνος, Α. Σαρή, Π. Λουρίδα, Π. Γαργαλιάνος-Κακολύρης.Tenofovir και νεφρός: παρακολούθησηεργαστηριακών παραμέτρων. 22ο Πανελλήνιο Συνέδριο AIDS, Αθήνα 26-28 Νοεμβρίου 2010
    2.       Π. Λουρίδα, Α. Σαρή, Δ.Νακοπούλου, Κ. Ντίνος, Σ. Κασιάκου, Π. Γαργαλιάνος-Κακολύρης. Επίπεδαβιταμίνης D σε HIV θετικούς ασθενείς. 22ο Πανελλήνιο Συνέδριο AIDS, Αθήνα 26-28 Νοεμβρίου 2010
    3.       Γ. Ξυλωμένος, Α. Σαρή, Κ.Ντίνος, Σ. Κασιάκου, Π. Λουρίδα, Π. Γαργαλιάνος-Κακολύρης. Ανοσιακήκατάσταση των HIV ασθενών κατά τη διάγνωση. 22ο Πανελλήνιο Συνέδριο AIDS, Αθήνα 26-28 Νοεμβρίου 2010
     
  • ΣΥΓΓΡΑΦΗ ΚΕΦΑΛΑΙΩΝ ΣΕ ΒΙΒΛΙΑ

    Φαλάγγας Μ., ΚασιάκουΣ. Πυρετός σε ασθενείς με ουδετεροπενία, στο σύγγραμμα: Καταστάσειςεπείγουσας ιατρικής στη λοιμωξιολογία, Β. Σεϊτανίδης, Κ. Γεωργιλής(εκδότες). Ιατρικές εκδόσεις Βήτα, Αθήνα 2003, σελ. 51 – 72. 

Παθολογικό Ιατρείο

 

Λέρου 50 Περιστέρι

 

τηλ. 2105761201